title: A review of the smallpox vaccine adverse events active surveillance system.
abstract: In response to concern about smallpox possibly being used as a biological weapon, the President of the United States launched the National Smallpox Pre-Event Vaccination Program on 13 December 2002. Given safety concerns, identifying potentially serious adverse events (SAEs) was an essential tool of the program. To monitor for SAEs, both enhanced passive surveillance and active surveillance systems were used. The enhanced passive system was built, in part, on the existing Vaccine Adverse Event Reporting System; the active system was implemented 24 January 2003. During January 2003-May 2005, the active system detected only 1 SAE in addition to those reported through the enhanced passive system. Furthermore, the active system was not universally used by states. With the enhancements to passive surveillance, the performance of enhanced passive surveillance was comparable to that of active surveillance. However, an active surveillance system may be important when there is no enhanced passive surveillance system available.
authors.affiliation: National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: Tracy N
authors.initials: TN
authors.lastname: Thomas
authors.forename: Susan
authors.initials: S
authors.lastname: Reef
authors.forename: Linda
authors.initials: L
authors.lastname: Neff
authors.forename: Mercedes M
authors.initials: MM
authors.lastname: Sniadack
authors.forename: Gina T
authors.initials: GT
authors.lastname: Mootrey
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D018563:Disease Notification / Q000379:methods / Q000706:statistics & numerical data*; D006282:Health Personnel; D006801:Humans; D032541:Mass Vaccination / Q000009:adverse effects*; D008889:Military Personnel; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D012189:Retrospective Studies; D018571:Sentinel Surveillance; D012899:Smallpox / Q000276:immunology*; D012900:Smallpox Vaccine / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology
chemical_list: C078786:DryVax vaccine; D012900:Smallpox Vaccine